your market intelligence analyst
Search Results
849 results
Your search is now limited to «Immunotherapy» expert search.
PMLiVE 05/28/2020 06:47
Gilead Sciences has accelerated its push into cancer with a wide-ranging deal with Arcus that gives it access to the bulk of the biotech’s immuno-oncology pipeline.
More from PMLiVE:
GlobeNewswire 05/27/2020 16:01
The company has completed dosing in the pivotal study in patients with metastatic melanoma and is currently conducting a pivotal study in patients with advanced cervical cancer.
More from GlobeNewswire: 05/27/2020 14:26
May 27 2020 Researchers of McMaster University and the University of Toronto have developed a promising immunotherapy treatment for a deadly form of adult brain cancer called glioblastoma.
More from
Healio News 05/27/2020 11:37
The new indication applies to use of the two agents combined with limited chemotherapy as first-line treatment of adults with metastatic or recurrent non-small cell lung cancer who do not have EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
More from Healio News: 05/27/2020 08:24
Condition : Esophageal Malignant Neoplasm, Local Recurrence Interventions : Drug: Procedural death 1; Drug: Capecitabine; Radiation: Radiotherapy; Drug: Placebo Sponsor : The First Affiliated Hospital of Henan University of Science and Technology Not yet recruiting.
More from 05/27/2020 07:17
Gilead Sciences Inc:
More from
Business Wire 05/27/2020 07:11
Arcus currently has a clinical-stage pipeline of four immuno-oncology programs, as well as an active oncology discovery pipeline with six preclinical compounds that target critical biological pathways.
More from Business Wire:
FeedNavigator (EU) 05/27/2020 06:20
However, other studies showed a positive correlationship between the AGE/RAGE interaction and development of pancreatic and gastric cancers, and melanoma.
More from FeedNavigator (EU):
PR Newswire 05/27/2020 03:00
Treatment strategies that aim at recruiting the immune system to attack and kill tumor cells hold great promise and are currently a main focus in global oncology research.
More from PR Newswire:
Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer.
More from International Journal of COPD:
Onclive 05/26/2020 16:13
Gilberto Lopes, MD Immunotherapy should be continued for up to 2 years in patients with metastatic lung cancer who are responding to the treatment, unless they experience disease progression or excessive toxicity, according to Gilberto de Lima Lopes, MD.
More from Onclive:
HIT Consultant Media 05/26/2020 11:13
Oncology Analytics’ prior authorization platform is used by physicians to support 5 million health plan members in the US and Puerto Rico and covers the full spectrum of therapeutics, across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care ...
More from HIT Consultant Media:
Bio-Medicine.Org 05/26/2020 09:41
Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies.
More from Bio-Medicine.Org:
Researchers follow patients with lung cancer all the way from diagnosis through to either disease relapse or cure after surgery, tracking and analyzing how their cancer develops.
More from Healthcare Sales & Marketing Network:
By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and ADCs – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and, one day, eliminate cancer as a cause of death.
More from Pharmaceutical Business Review:
Korean Biomedical Review 05/26/2020 04:34
The permit has significance as it is the first case of Keytruda and Lenvima combination therapy and Keytruda’s female cancer indication,” MSD’s Oncology Business Unit Director Choi Jae-yoon said.
More from Korean Biomedical Review:
PharmaTimes 05/26/2020 03:53
AstraZeneca is teaming up with genomic analysis group ArcherDX to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC.
More from PharmaTimes:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications